AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 182.37B -1.8% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.35 |
| Forward PE | 14.67 |
| Dividend | 2.39 (2.00%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 1,466,343 |
| Open | 11,810 |
| Previous Close | 11,758 |
| Day's Range | 11,708 - 11,960 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 15,746.06 (+34.49%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,746p, which is an increase of 34.49% from the latest price.
News
AZN Looks 12.0% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 12.0% Undervalued on GF Value⢠as Dividend Remains Attractive
AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer
AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster.
Astrazeneca's breast cancer drug fails late-stage trial
AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
AstraZeneca down 2% at $157 after SERENA-4 trial update
16:26 EDT AstraZeneca (AZN) down 2% at $157 after SERENA-4 trial update
AstraZeneca says SERENA-4 trial did not meet primary objective
The company states: “The SERENA-4 Phase III trial of AstraZeneca’s (AZN) Etcamah (camizestrant) in combination with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, did not meet the primary...
Running costs of Covid vaccine damage scheme double the amount paid to victims
The government scheme to support people injured by Covid vaccines and other jabs has cost £83m to run since March 2022, new figures have revealed. The amount spent on administration costs and medical ...
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
(RTTNews) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
Stocks and Shares ISA returns by 2035: AZN merger cloud changes the maths
A Stocks and Shares ISA compounding at 9% a year can turn a £10,000 lump sum into roughly £21,000 by 2035, but the stock most often proposed as the engine for those returns, AstraZeneca (AZN), is now ...
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
HSBC raised the firm’s price target on AstraZeneca (AZN) to 13,920 GBp from 13,750 GBp and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare…
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough
AZN Looks 12.5% Undervalued on GF Valueâ¢
AZN Looks 12.5% Undervalued on GF Valueâ¢
AstraZeneca drug reduces lung disease flare-ups in late-stage trials
Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona.
Lighting Round: I have never liked Grab Holdings, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Joby Aviation, Simon Property Group, Grab Holdings, Trinity Industries, and AstraZeneca.
Cramer's lightning round: 'I am not going to put my money on AstraZeneca'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
AstraZeneca initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of AstraZeneca (AZN) with an Outperform rating and 14,500 GBp price target The firm believes AstraZeneca offers the most compelling risk/reward in European Union pharma....
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study
(RTTNews) - Amgen Inc.(AMGN) on Tuesday reported that the Phase 3 DeLLphi-305 study, which evaluated IMDELLTRA (tarlatamab-dlle) in combination with AstraZeneca PLC's(AZN) Imfinzi (durvalumab) versus ...
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Potential Soars
AstraZeneca Transcript: Investor update
Tozorakimab demonstrated significant reductions in COPD exacerbations across all patient subgroups, supporting its potential as a first-in-class biologic for a broad population. With FDA priority review and a projected peak sales exceeding $5 billion, it is positioned to address a large unmet need and drive long-term growth alongside a robust pipeline.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
AZN Looks 10.1% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.1% Undervalued on GF Value⢠as Dividend Remains Attractive
AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD
(RTTNews) - AstraZeneca PLC (AZN) announced positive results from the Phase III OBERON and TITANIA trials evaluating Tozorakimab in chronic obstructive pulmonary disease (COPD).
AZN Looks 10.1% Undervalued on GF Value⢠Amid Strong Dividend Sustainability
AZN Looks 10.1% Undervalued on GF Value⢠Amid Strong Dividend Sustainability
AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.
Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningf...